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Tamoxifen activity against Plasmodium 
in vitro and in mice
Ada Weinstock1†, Julio Gallego‑Delgado2,3,4*† , Cláudia Gomes4, Julian Sherman4, Cyrus Nikain1, 
Sandra Gonzalez4, Edward Fisher1 and Ana Rodriguez4 
Abstract 
Background: Tamoxifen is an oestrogen receptor modulator that is widely used for the treatment of early stage 
breast cancer and reduction of recurrences. Tamoxifen is also used as a powerful research tool for controlling gene 
expression in the context of the Cre/loxP site‑specific recombination system in conditional mutant mice.
Methods: To determine whether the administration of tamoxifen affects Plasmodium growth and/or disease out‑
come in malaria, in vitro studies assessing the effect of tamoxifen and its active metabolite 4‑hydroxytamoxifen on 
Plasmodium falciparum blood stages were performed. Tamoxifen effects were also evaluated in vivo treating C57/B6 
mice infected with Plasmodium berghei (ANKA strain), which is the standard animal model for the study of cerebral 
malaria.
Results: Tamoxifen and its active metabolite, 4‑hydroxytamoxifen, show activity in vitro against P. falciparum (16.7 to 
5.8 µM IC50, respectively). This activity was also confirmed in tamoxifen‑treated mice infected with P. berghei, which 
show lower levels of parasitaemia and do not develop signs of cerebral malaria, compared to control mice. Mice 
treated with tamoxifen for 1 week and left untreated for an additional week before infection showed similar parasitae‑
mia levels and signs of cerebral malaria as control untreated mice.
Conclusions: Tamoxifen and its active metabolite, 4‑hydroxytamoxifen, have significant activity against the human 
parasite P. falciparum in vitro and the rodent parasite P. berghei in vivo. This activity may be useful for prevention of 
malaria in patients taking this drug chronically, but also represents a major problem for scientists using the condi‑
tional mutagenic Cre/LoxP system in the setting of rodent malaria. Allowing mice to clear tamoxifen before starting 
a Plasmodium infection allows the use the Cre/LoxP conditional mutagenic system to investigate gene function in 
specific tissues.
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Background
Tamoxifen is the most used selective oestrogen-receptor 
modulator to prevent and treat oestrogen receptor posi-
tive breast cancer. More than 40  years after tamoxifen 
discovery, it still remains as one of the most effective 
therapies for cancer treatment [1]. Due to its low cost and 
safety profile, its use is now generalized worldwide [2].
Tamoxifen is also well known by the scientific com-
munity, not only for its outstanding anticancer prop-
erties, but also for its role as exogenous ligand for the 
inducible Cre/loxP site-specific recombination system. 
The Cre/loxP site-specific recombination system is a 
powerful and extensively used tool for controlling gene 
expression. The Cre/LoxP system allows researchers to 
tightly control gene expression in a tissue and time spe-
cific manner. These conditional mutagenic systems con-
sist of the gene for Cre-recombinase fused to mutated 
hormone-binding domains of the oestrogen recep-
tor that can be activated by administration of tamox-
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resource has become an essential tool for gene target-
ing experiments in almost every medical research field. 
Surprisingly, published studies using this conditional 
mutagenic technology in the setting of experimental 
malaria, where rodent infections are the most common 
model used for research in this disease, were not found.
The last World Health Organization (WHO) malaria 
report confirms an estimated 219 million new cases of 
malaria and more than 400,000 deaths, approximately 
the same number observed during the previous 2 years 
[4]. The stagnation in the reduction of cases and deaths, 
keeps malaria as one of the top 5 causes of death in 
children worldwide, claiming a child’s life every 2 min 
[5]. The combination of experimental models of malaria 
and Cre/loxP conditional mutagenic system would be 
a powerful strategy to further understand the mecha-
nisms regulating susceptibility to malaria. However, 
this system requires the use of tamoxifen to induce 
Cre/loxP recombination in mice.
Tamoxifen has shown additional activities other than 
anticancer including antibacterial, antiviral and even 
antiparasitic (anti-echinococcus and anti-leishmania) 
effects [1]. Moreover, tamoxifen interferes in vitro with 
the glucosylceramidesynthase and sphingomyelin syn-
thase levels of Plasmodium falciparum affecting the 
bioactive sphingolipid pathway [6]. Although it has 
been reported that tamoxifen has no effect over P. fal-
ciparum growth at concentrations lower than 10  µM 
[7], there are no studies about the effect of this drug at 
higher concentrations in vitro or on other Plasmodium 
spp. in vivo.
In this work, the activity of tamoxifen and its active 
metabolite 4-hydroxytamoxifen in  vitro against P. fal-
ciparum was evaluated. The impact of tamoxifen in 
Plasmodium berghei infections in mice was also ana-
lysed, including parasitaemia levels and the develop-
ment of neurological signs in the experimental cerebral 
malaria mouse model. Finally, an alternative protocol 
that allows the use of Cre/loxP conditional mutagenic 
system for the study of Plasmodium infections and 
development of cerebral malaria in mouse models is 
provided.
Methods
This study strictly followed the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocol was reviewed 
and approved by the Institutional Animal Care and Use 
Committee of New York University School of Medicine, 
which is fully accredited by the Association for Assess-
ment and Accreditation Of Laboratory Animal Care 
International (AAALAC).
Determination of IC50 against Plasmodium falciparum 
in vitro
Using 96-well plates, 100  µl of P. falciparum growth 
medium (RPMI 1640, 25  mM HEPES, 0.1  mg/ml gen-
tamicin, 0.05  mg/l hypoxanthine [pH 6.75]), sup-
plemented with 0.25% sodium bicarbonate and 0.5% 
Albumax II (Invitrogen), were added to each well. 
Compounds from a DMSO stock at 10 mM were then 
serially diluted in triplicate. DMSO at the highest con-
centration used (0.5%) was tested in parallel, showing 
no differences from the control samples.
Plasmodium falciparum infected erythrocytes (RBCs) 
were incubated at 0.25% parasitaemia and 5% haema-
tocrit and treated with increasing doses of tamoxifen, 
its bioactive metabolite 4-hydroxytamoxifen, and chlo-
roquine as positive control (IC50 < 0.78  µM), for 96  h 
in a gas chamber containing 90% nitrogen, 5% carbon 
dioxide and 5% oxygen. After incubation, the parasite 
was frozen for 24 h at − 80 °C, then thawed for 4 h and 
transferred to a new 96-well plate.  0.01% SYBR Green 
I nucleic acid staining dye (Molecular Probes) mixed 
with lysis buffer (20 mM Tris at pH 7.5, 5 mM EDTA, 
0.008% saponin, and 0.08% Triton X-100) was added 
to each well and incubated at room temperature on a 
shaker for 1 h. Fluorescence was measured using exci-
tation and emission wavelengths of 485 and 530  nm, 
respectively.
Activity of tamoxifen against P. falciparum blood stage 
in vitro
Plasmodium falciparum cultures were synchronized 
using sorbitol 5%. Synchronized cultures at ring/
trophozoite or schizont/ring stages were incubated 
with 4-hydroxytamoxifen at 25  μM or DMSO 0.5% as 
a control for 24 or 18  h and parasite densities were 
quantified.
Experimental P. berghei infections
Both males and females 5 weeks old C57/B6 mice were 
purchased from Taconic Farms Inc. Animals were 
infected by i.p. inoculation of 200 µl of sterile PBS con-
taining different concentrations of P. berghei (ANKA 
strain) infected RBCs (1 × 106, 5 × 106 or 20 × 106). 
Parasitaemia was determined in Giemsa-stained thin 
blood smears by microscopy. Determination and sever-
ity of experimental cerebral malaria was scored as pre-
viously described [8] based on appearance (Normal = 0; 
Coat ruffled = 1; Coat staring/panting = 2) and behav-
iour (Normal = 0; Hunched = 1; Partial paralysis = 3; 
Convulsions = 4). Tamoxifen was administered in the 
diet (Envigo) at 40 mg/kg per day.
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Statistical analyses
Significance for intra-erythrocytic P. falciparum growth 
was calculated using 2-way ANOVA. Significance for 
parasitaemia was calculated for each day individually, 
using unpaired t test for experiments with 2 groups 
and 1-way ANOVA for experiments with more than 
2 groups. The area under the curve was calculated for 
disease score and statistical analysis was performed 
using an unpaired t test. Survival curves were com-
pared using Log-rank (Mantel–Cox) test. p ≤ 0.05 was 
considered significant. Data was analysed using Graph-
Pad Prism 7.05.
Results
Tamoxifen inhibits P. falciparum growth in vitro
To test whether tamoxifen has any direct effects on P. fal-
ciparum growth, an in vitro growth assay was performed. 
The parasite was treated with increasing doses of tamox-
ifen, or its bioactive metabolite 4-hydroxytamoxifen [9]. 
Parasite viability was measured after 96 h.
These results show that tamoxifen and 4-hydroxyta-
moxifen have IC50s against P. falciparum of 16.7 µM and 
5.8  µM, respectively (Fig.  1). These results indicate that 
the tamoxifen bioactive metabolite is more effective than 
the original compound, predicting a significant in  vivo 
anti-Plasmodium activity.
To characterize in more detail the effect of 4-hydroxy-
tamoxifen on  P. falciparum-infected RBCs, this com-
pound was added to  in vitro-synchronized cultures of 
the parasite and followed their development. When 
4-hydroxytamoxifen was added to cultures of ring/
trophozoite stages for 24 h, an almost complete arrest of 
parasite growth was observed (Fig.  2a), indicating that 
4-hydroxytamoxifen affects early intra-erythrocytic para-
site development. The addition of 4-hydroxytamoxifen to 
cultures in the schizont stage for 18 h did not affect the 
progression from schizonts into rings (Fig. 2b), indicating 
that merozoite release and reinvasion of new RBCs was 
not affected.
Tamoxifen inhibits P. berghei growth and the development 
of cerebral malaria in mice
Since tamoxifen and its bioactive form impair parasite 
growth in  vitro, the tamoxifen effect on infected mice 
was examined. For this purpose, C57/B6 mice were 
treated with tamoxifen for 1 week prior to infection with 
 106 P. berghei infected RBCs. Tamoxifen treatment con-
tinued throughout the course of infection. At day 3 post 
infection, parasitaemia was significantly higher in the 
control group (1.56% ± 0.39) compared with the tamox-
ifen treated mice (0.64% ± 0.1). The differences in para-
sitaemia increased over time with a 2.7-fold difference 
between control and treated mice at day 5 post infection 
that continued at day 7 (Fig. 3a).
Mice were closely monitored for the development 
of neurological signs of cerebral malaria. Interest-
ingly, mice treated with tamoxifen did not develop 
cerebral malaria. At day 6 post infection 100% of the 
control mice (− Tam), compared to 10% of tamoxifen-
treated mice (+ Tam), presented typical neurological 
signs associated with cerebral malaria (Fig.  3b). Addi-
tionally, the severity of the disease was much greater 
in the control mice, as indicated by the disease score 
(Fig. 3b). Accordingly, the control group presented sig-
nificantly higher mortality. At day 7.5 post infection, all 
of the tamoxifen treated mice had survived while all of 
Fig. 1 Determination of Tamoxifen antiplasmodial activity in vitro. Plasmodium falciparum cultures were incubated with increasing doses of 
tamoxifen (a) or 4‑hydroxytamoxifen (b) for 96 h. Parasite viability was measured using SYBR Green fluorescence and the half‑maximal inhibitory 
concentration (IC50) was calculated for each drug. Results show the average and standard deviation of triplicated determinations for each 
concentration
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the control animals had died (Fig.  3c). The tamoxifen 
treated group was monitored for additional 2  weeks, 
in which none of the mice showed signs of cerebral 
malaria. Taken together, these data demonstrate that 
tamoxifen treatment inhibits parasite growth and pre-
vents the development of cerebral malaria.
Alternative strategies to study cerebral malaria in genetic 
mouse models that require tamoxifen
Finding that tamoxifen inhibits the development of cer-
ebral malaria in mice indicates that the use of the Cre/
LoxP recombination system in mice cannot be used 
for the study of cerebral malaria. To overcome this 
Fig. 2 Tamoxifen active metabolite, 4‑hydroxytamoxifen, inhibits intra‑erythrocytic P. falciparum growth. Plasmodium falciparum cultures 
synchronized at ring/trophozoite (a) or schizont (b) stages at the beginning of the experiment were incubated with vehicle (DMSO 0.5%) as a 
control (c), or 4‑hydroxytamoxifen (4‑OH Tam) at 25 μM for 24 h (a) or 18 h (b). Quantification results for parasite stages at 24 h (a) or 18 h (b) after 
addition of tamoxifen show average and standard deviation of quadruplicated determinations for rings/trophozoites (white bars), and schizonts 
(gray bars). Statistical significance was calculated using 2‑way ANOVA (****p < 0.0001), ns (not significant). The panels show representative images of 
parasites at the indicated time points
Fig. 3 Tamoxifen has antiplasmodial activity in vivo and inhibits experimental cerebral malaria in mice. CB57/B6 mice were treated with tamoxifen 
40 mg/kg per day 1 week prior infection with P. berghei ANKA and during the course of the infection (squares) versus untreated control group 
(circles). Animals treated with tamoxifen exhibited lower parasitaemia levels (a), lower neurological signs of cerebral malaria (b) and a 100% survival 
ratio after 7 days post‑infection (c) compared with control group. Statistical significance was calculated using an unpaired t test (a, b) or Log‑rank 
(Mantel–Cox) test (c) (*p < 0.05; ***p < 0.01; ****p < 0.0001)
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limitation, an attempt was made to find the conditions to 
induce cerebral malaria in mice treated with tamoxifen to 
induce Cre/LoxP recombination.
Since the induction of cerebral malaria in mice is 
dependent on the amount of inoculum used for infec-
tion [10], we tested whether the inhibition of cerebral 
malarial development by tamoxifen could be overcome 
by increasing the inoculum dose. Three groups of mice 
were subjected to tamoxifen treatment for 1 week prior 
to infection with 1, 5 or 20 million P. berghei infected 
RBCs. Parasite growth and signs of cerebral malaria were 
monitored thereafter, with the mice subjected to con-
tinuous tamoxifen treatment. Results show that all the 
groups had similar parasite levels throughout the experi-
ment (Fig. 4a) and none of the mice in any of the treated 
groups developed signs of cerebral malaria.
The next step was to investigated whether an alterna-
tive approach where tamoxifen would be used prior to 
infection to induce the required Cre activity, followed 
by a period without treatment to allow the drug to be 
eliminated from the mice, would result in normal growth 
of the parasite and the development of cerebral malaria. 
To test this hypothesis, mice were treated with tamoxifen 
for 1 week and then rested, without any further tamox-
ifen treatment, for 1 or 2  weeks. Thereafter, mice were 
injected with  106 P. berghei infected RBCs and carefully 
monitored for parasitaemia, disease signs and survival. 
These results show that resting for either 1 or 2  weeks 
post tamoxifen treatment enables parasite growth to 
levels similar to control untreated mice (Fig.  4b). Signs 
of cerebral malaria also increased similarly in all groups 
(Fig. 4c). Signs started to appear in all groups at day 5.5 
post infection and the severity of the disease was com-
parable at all times. Survival was also similar between 
the groups (Fig. 4d), with all mice dying by day 6.5 post 
infection. Hence, these data demonstrate that tamoxifen 
directly affects the survival of P. berghei, however, pre-
treatment with tamoxifen does not significantly influence 
parasitaemia and the course of cerebral malaria when 
administered at least 1 week before infection.
Fig. 4 Alternative strategy to study cerebral malaria in mouse models that require tamoxifen. CB57/B6 mice were treated with tamoxifen 40 mg/
kg per day one week prior infection with 1 million (circles), 5 millions (squares) or 20 millions (triangles) P. berghei ANKA infected RBCs. During the 
course of the infection animals continued being treated with tamoxifen and parasitaemia levels were monitored showing no differences between 
groups (a). As an alternative approach to study cerebral malaria in mouse models that require the use of tamoxifen, CB57/B6 mice were randomized 
into 3 groups: control group without tamoxifen (circles), treated with tamoxifen for 1 week and then rested, without any further tamoxifen 
treatment, for 1 week (squares) or 2 weeks (triangles) before infection with 1 million P. berghei infected RBCs. All groups developed comparable 
levels of parasitaemia (b), developed neurological signs of cerebral malaria (c) and did not differ in survival (d)
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Discussion
Regardless of the constant efforts to reduce the burden 
of the disease, malaria was responsible for more than 
260,000 deaths in children under 5  years in 2017 alone 
[4]. Emergence of new resistant strains of Plasmodium 
parasites to classical anti-malarial drugs, but in par-
ticular to artemisinin-based combination therapy [11, 
12], are jeopardizing the international efforts to combat 
malaria and increase the need for the development of 
new therapies against this infection. Here we report the 
anti-malarial effects of tamoxifen, a drug that has been 
used worldwide for the treatment of breast cancer for 
over 30 years. Our observation that tamoxifen has potent 
activity against P. falciparum in vitro and induces a sig-
nificant decrease of P. berghei growth in mice, positions 
this drug as a possible candidate for development as an 
anti-malarial. These data also suggest that patients tak-
ing tamoxifen for extended periods of time, as it is fre-
quent when prescribed for prevention of recurrences or 
in genetically identified high-risk patients, may present 
increased protection against malaria.
Tamoxifen is also active against another protozoan 
parasite, Leishmania, with an IC50 of 11  µM in  vitro 
[13], which is similar to these findings for Plasmodium 
(16  µM). Tamoxifen has been proposed as a partner in 
drug-combination therapies anti-Leishmania, since it 
increased the effectivity of classical agents against this 
parasite in mice with leishmaniasis [14, 15]. Additionally, 
it was shown that Leishmania  is not prone to develop 
resistance to tamoxifen, which is an important feature for 
diseases such as malaria and leishmaniasis where drug 
resistance is frequently found in the field [16].
Of all malaria cases, only 1% of the patients develop 
severe malaria, a life-threatening disease [17]. The most 
common complications of severe malaria are cerebral 
malaria, acute respiratory distress, severe anaemia and 
acute kidney injury [18]. Patients of severe malaria can 
rapidly deteriorate, and mortality rate can exceed 50% 
even when anti-malarial treatment is provided [19]. 
Advancing the understanding of severe malaria patho-
genesis is essential to develop new adjunctive therapies to 
treat these deadly complications of malaria. In that sense, 
rodent malaria models of human severe malaria are key 
to basic discovery, drug testing and pathogenesis research 
[20]. Rodent malaria models have raised some criticisms 
in the scientific community due to their limitations in 
reproducing the human disease; however, they have pro-
vided critical insights into the pathophysiological mecha-
nisms involved in severe malaria [21]. This study shows 
that the susceptibility of Plasmodium to tamoxifen would 
interfere with the use of the Cre/loxP site-specific recom-
bination system for the study of malaria since it interferes 
with the levels of infection and prevents the development 
of experimental cerebral malaria. Here is presented an 
alternative protocol that can overcome this problem by 
allowing the mice to clear tamoxifen levels during a week 
after treatment. Since only 0.3% of tamoxifen adminis-
tered orally reaches the circulation, and blood tamoxifen 
concentration decreases by ~ 90% at 7 days post admin-
istration in mice [22], it is expected that the levels after 
1 week would be negligible. It is important to note that 
this protocol may not be adequate when Cre recombina-
tion needs to occurs in tissues with high turnover rates, 
such as epithelial cells, since recombinant cells would 
reach the end of their life span and be replaced before the 
end of the week resting period.
Plasmodium blood-stage infection is confined to the 
circulation and associated immune organs, which are 
mostly constituted by cell types with low turnover rates, 
such as endothelial [23], and leukocytes [24], therefore, 
recombinant cells are expected to remain functional in 
the tissues for sufficient amount of time to complete a 
Plasmodium infection.
Conclusion
Tamoxifen and its active metabolite, 4-hydroxytamox-
ifen, have antiplasmodial activity in  vitro and in  vivo. 
Since tamoxifen is an inexpensive, well-tolerated drug 
with an adequate safety profile, development of this drug 
for use in anti-malarial therapies may be warranted.
However, this anti-Plasmodium activity may also jeop-
ardize the use of the conditional mutagenic Cre/LoxP 
system in the setting of rodent experimental models of 
malaria.
As an alternative strategy, we propose administrating 
tamoxifen for 1 week and keeping mice free of tamoxifen 
for another week prior to infection and after. With this 
approach, parasitaemia and cerebral malaria signs can be 
restored to control levels. This alternative strategy would 
be appropriate to investigate specific gene function in tis-
sues with a low turnover, such as endothelium or glia.
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